New cancer therapies at international conference in Amsterdam

Amsterdam/Lugano, March 16, 2006 - The 4th International Symposium on Targeted Anticancer Therapies (TAT 2006), to be held in Amsterdam, The Netherlands, March 16-18, 2006, co-organized by the NDDO Research Foundation and the European Society for Medical Oncology (ESMO), provides updates on emerging new therapies for the treatment of cancer. Several new, so-called targeted anticancer agents are likely to be approved for use in daily practice in the near future. The ones that seem closest to obtaining marketing approval in the European Union are sorafenib (Nexavar) and sunitinib (Sutent). Both are being developed for kidney cancer (renal cell cancer) and have recently been approved by the US Food and Drug Administration. European marketing applications are under review by the European Medicines Agency (EMEA).

Sorafenib and sunitinib block specific target molecules that are important for tumor growth and development. They are considered real breakthroughs in the treatment of advanced kidney cancer, a disease that is difficult to treat with currently available drugs. No new drugs for kidney cancer have been introduced in the past ten years. At TAT 2006, sorafenib and sunitinib will be reviewed extensively, in particular by Professor Martin Gore of the Royal Marsden Hospital in London, who will present a keynote lecture on emerging treatments for kidney cancer during the Opening Ceremony on March 16.

Many targeted anticancer therapies, covering a wide variety of targets in tumor tissue or the tumor's environment, are the subject of extensive research and development activities worldwide. Many targeted agents are being tested in clinical trials and are showing promising results in patients with different types of cancers. Several targeted agents have already been approved for cancer therapy by regulatory agencies worldwide, including, but not limited to, bevacizumab (Avastin), cetuximab (Erbitux) and erlotinib (Tarceva). Updates on these agents and many

Contact: Dr. Marinus W. Lobbezoo
European Society for Medical Oncology

Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Newly created cancer stem cells could aid breast cancer research
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. No evidence that widely prescribed statins protect against prostate cancer
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. New test improves detection of liver cancer
9. High-intensity ultrasound may launch attack on cancer, wherever it lurks
10. Unknotting DNA clue to cancer syndrome
11. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer

Post Your Comments:

(Date:6/28/2020)... ... , ... In an upcoming episode scheduled for the fall of 2020, Advancements ... (POCT). Check local listings for more info. , Today, the majority of testing is ... labs throughout the country. Results are then available several days later. Now, in an ...
(Date:6/23/2020)... (PRWEB) , ... June 23, ... ... provider of gene-to-protein and monoclonal antibody development services, today announced that the ... products and services to the pharmaceutical, diagnostics, and research industries. The decision ...
(Date:6/23/2020)... ... 2020 , ... The field of quantitation of large molecules or proteins has ... area. However, the use of mass spectrometry in this field has gained a lot ... do you choose which approach to use (LBA or MS)?” In many cases, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine today revealed that ... FDA compliance consulting has been named on its annual Inc. 5000 list, the ... unique look at the most successful companies within the American economy’s most dynamic ...
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... radar transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and ... can drive one or two switches in a push-pull configuration; yielding fast fall ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted ... will cover the history of eSource, the reasons it did not take off as ... to site source, the industry is moving towards capturing data electronically for clinical trials ...
Breaking Biology Technology:
Cached News: